Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Fate Therapeutics Inc Announces Pricing Of Initial Public Offering


Tuesday, 1 Oct 2013 08:45am EDT 

Fate Therapeutics Inc announced the pricing of its Initial Public Offering (IPO) of 6,666,667 shares of its common stock price to the public of $6.00 per share, before underwriting discounts. The shares are scheduled to begin trading on The NASDAQ Global Market under the ticker symbol FATE on October 1, 2013. In addition, Fate has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the same price. The offering is expected to close on October 4, 2013, subject to customary closing conditions. Cowen and Company, LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Wedbush Securities Inc. is acting as a co-manager for the offering. 

Company Quote

3.75
-0.16 -4.09%
28 Nov 2014